Novel therapeutic targets for enteric nervous system disorders

Trends in Pharmacological Sciences

Volumn 28, Issue 9, 2007, Pages 473-481

  De Giorgio, Roberto ^a   Barbara, Giovanni ^a   Furness, John B ^b   Tonini, Marcello ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; BENZOFURAN DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CISAPRIDE; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; ION CHANNEL; KAPPA OPIATE RECEPTOR AGONIST; METOCLOPRAMIDE; MOSAPRIDE CITRATE; OPIATE RECEPTOR; PROKINETIC AGENT; PROTEINASE ACTIVATED RECEPTOR; PRUCALOPRIDE; RENZAPRIDE; SEROTONIN; SEROTONIN 1 AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN 7 ANTAGONIST; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; BLOATING; CARCINOID; DIARRHEA; DRUG TARGETING; DYSPEPSIA; ENTERITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; HUMAN; ILEUS; INTESTINE INNERVATION; INTESTINE MOTILITY; IRRITABLE COLON; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; GASTROINTESTINAL DISEASES; HUMANS; NERVOUS SYSTEM DISEASES; RECEPTORS, PROTEINASE-ACTIVATED; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 34548400223     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.08.003     Document Type: Review

References (74)

1. Drossman D.A. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 130 (2006) 1377-1390
2. Longstreth G.F., et al. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am. J. Gastroenterol. 98 (2003) 600-607
3. Buéno L., et al. Serotonergic and non-serotonergic targets in the pharmacotherapy of visceral hypersensitivity. Neurogastroenterol. Motil. 19 (2007) 89-119
4. Furness J.B. The Enteric Nervous System (2006), Blackwell Publishing pp. 277
5. Jones M.P., and Wessinger S. Intestinal motility. Curr. Opin. Gastroenterol. 22 (2006) 111-116
6. Talley N.J. Irritable bowel syndrome. Intern. Med. J. 36 (2006) 724-728
7. Tonini M. 5-Hydroxytryptamine effects in the gut: the 3, 4 and 7 receptors. Neurogastroenterol. Motil. 17 (2005) 637-642
8. Gershon M.D., and Tack J. The serotonin signalling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132 (2007) 397-414
9. Tonini M., and Pace F. Drugs acting on serotonin receptors for the treatment of functional GI disorders. Dig. Dis. 24 (2006) 59-69
10. Chey W.D., et al. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. Expert Opin. Investig. Drugs 14 (2005) 185-193
11. 3 antagonist treatment?. Neurogastroenterol. Motil. 19 (2007) 77-84
12. Fujita T., et al. Effect of MKC-733, a 5-HT3 receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study. J. Clin. Pharm. Ther. 30 (2005) 611-622
13. 4 receptors in wild-type mice and analyses of intestinal motility in 5-HT4 knockout mice. Gastroenterology 124 (2003) A-342
14. 2B receptor antagonist in vitro and in vivo. Br. J. Pharmacol. 143 (2004) 549-560
15. Tonini M., et al. Cardiac adverse effects of gastrointestinal prokinetics. Aliment. Pharmacol. Ther. 13 (1999) 1585-1591
16. Tack J., et al. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 54 (2005) 1707-1713
17. Balestra, B. et al. Role of 5-HT receptors in modulating propulsive activity and accommodation in the guinea-pig distal colon. Pharmacol. Res. (in press)
18. Tack J., et al. Role of tension receptors in dyspeptic patients with hypersensitivity to gastric distention. Gastroenterology 127 (2004) 1058-1066
19. Tack J., and Lee K.J. Pathophysiology and treatment of functional dyspepsia. J. Clin. Gastroenterol. 39 (2005) S211-S216
20. Grider J.R., et al. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 115 (1998) 370-380
21. Crowell M.D., et al. The effects of tegaserod, a 5-HT receptor agonist, on gastric emptying in a murine model of diabetes mellitus. Neurogastroenterol. Motil. 17 (2005) 738-743
22. Scott L.J., and Perry C.M. Tegaserod. Drugs 58 (1999) 491-498
23. Mackie A.D., et al. The effects of renzapride, a novel prokinetic agent, in diabetic gastroparesis. Aliment. Pharmacol. Ther. 5 (1991) 135-142
24. Camilleri M., et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 2 (2004) 895-904
25. Tack J., et al. Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 23 (2006) 1655-1665
26. Potet F., et al. Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo K(+) channel. J. Pharmacol. Exp. Ther. 299 (2001) 1007-1012
27. Kadowaki M., et al. Effect of FK1052, a potent 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptor dual antagonist, on colonic function in vivo. J. Pharmacol. Exp. Ther. 266 (1993) 74-80
28. 4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit. Aliment. Pharmacol. Ther. 13 (1999) 1437-1444
29. Bharucha A.E. (2000) Effects of a serotonin 5-HT4 receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans. Gut 47 (2001) 667-674
30. Jin J.G., et al. Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptors. J. Pharmacol. Exp. Ther. 288 (1999) 93-97
31. Tonini M., et al. 5-HT7 receptors modulate peristalsis and accommodation in the guinea pig ileum. Gastroenterology 129 (2005) 1557-1566
32. Dunlop S.P., et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 125 (2003) 1651-1659
33. Barbara G., et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126 (2004) 693-702
34. Tonini M., et al. Pharmacology of the enteric nervous system. In: Brookes S., and Costa M. (Eds). Innervation of the Gastrointestinal Tract (2002), Taylor and Francis
35. Poonyachoti S., et al. Pharmacological evidence foe a 7-benzylidenenaltrexone-preferring opioid receptor mediating the inhibitory actions of peptidic δ- and μ-opioid agonists on neurogenic ion transport in porcine ileal mucosa. J. Pharmacol. Exp. Ther. 297 (2001) 672-679
36. Prado D. A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults. Scand. J. Gastroenterol. 37 (2002) 656-661
37. Farthing M.J. Antisecretory drugs for diarrheal disease. Dig. Dis. 24 (2006) 47-58
38. Holzer P. Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain. Eur. J. Pharmacol. 429 (2001) 177-193
39. Sengupta J.N., et al. Kappa, but not mu or delta, opioids attenuate responses to distention of afferent fibers innervating the rat colon. Gastroenterology 111 (1996) 968-980
40. Riviere P.J. Peripheral kappa-opioid agonists for visceral pain. Br. J. Pharmacol. 141 (2004) 1331-1334
41. Delgado-Aros S., et al. Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am. J. Physiol. Gastrointest. Liver Physiol. 284 (2003) G558-G566
42. Delvaux M., et al. Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. 20 (2004) 237-246
43. Camilleri M. Alvimopan, a selective peripherally acting mu-opioid antagonist. Neurogastroenterol. Motil. 17 (2005) 157-165
44. McLaughlin J., et al. Fatty acid chain length determines cholecystokinin secretion and effect on human gastric motility. Gastroenterology 116 (1999) 46-53
45. Borovicka J., et al. Role of cholecystokinin as a regulator of solid and liquid gastric emptying in humans. Am. J. Physiol. 271 (1996) G448-G453
46. Schwizer W., et al. Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: studies with the CCK antagonist loxiglumide. Gut 41 (1997) 500-504
47. Feinle C., et al. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 48 (2001) 347-355
48. Camilleri M. Treating irritable bowel syndrome: overview, perspective and future therapies. Br. J. Pharmacol. 141 (2004) 1237-1248
49. Peter S.A., et al. CCK1 antagonists: are they ready for clinical use?. Dig. Dis. 24 (2006) 70-82
50. Lecci A., et al. Tachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human. Auton. Neurosci. 126-127 (2006) 232-249
51. Faussone-Pellegrini M.S. Relationships between neurokinin receptor-expressing interstitial cells of Cajal and tachykininergic nerves in the gut. J. Cell. Mol. Med. 10 (2006) 20-32
52. Hill R.G., and Oliver K.R. Neuropeptide and kinin antagonists. Handb. Exp. Pharmacol. 177 (2007) 181-216
53. 3 receptor antagonist, talnetant, on rectal sensory function and compliance in healthy humans. Neurogastroenterol. Motil. (2007). http://www.blackwell-synergy.com 10.1111/j.1365-2982.2007.00934.x
54. Kris M.G., et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J. Clin. Oncol. 24 (2006) 2932-2947
55. Tonini M., et al. Tachykinin-dependent and -independent components of peristalsis in the guinea pig isolated distal colon. Gastroenterology 120 (2001) 938-945
56. Kamp E.H., et al. Combinations of neurokinin receptor antagonists reduce visceral hyperalgesia. J. Pharmacol. Exp. Ther. 299 (2001) 105-113
57. Izzo A.A., and Coutts A.A. Cannabinoids and the digestive tract. Handb Exp Pharmacol. 168 (2005) 573-598
58. Coutts A.A., et al. Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J. Comp. Neurol. 448 (2002) 410-422
59. MacNaughton W.K., et al. Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. Am. J. Physiol. Gastrointest. Liver Physiol. 286 (2004) G863-G871
60. Di Marzo V., et al. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 3 (2004) 771-784
61. Capasso R., et al. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 129 (2005) 941-951
62. Anon. Nabilone (Cesamet) for chemotherapy-induced nausea and vomiting. Med. Lett. Drugs Ther. 48 (2006) 103-104
63. Esfandyari T., et al. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am. J. Physiol. Gastrointest. Liver Physiol. 293 (2007) G137-G145
64. Cichewicz D.L. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 74 (2004) 1317-1324
65. Sanson M., et al. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol. Motil. 18 (2006) 949-956
66. Barbara G., et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 132 (2007) 26-37
67. Tachè Y., et al. CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br. J. Pharmacol. 141 (2004) 1321-1330
68. Liu S., et al. Expression of type 1 corticotropin-releasing factor receptor in the guinea pig enteric nervous system. J. Comp. Neurol. 481 (2005) 284-298
69. Sagami Y., et al. Effect of corticotrophin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 53 (2004) 958-964
70. Ossovskaya V.S., and Bunnett N.W. Protease-activated receptors: contribution to physiology and disease. Physiol. Rev. 84 (2004) 579-621
71. Cenac N., et al. Role for protease activity in visceral pain in irritable bowel syndrome. J. Clin. Invest. 117 (2007) 636-647
72. Linden D.R., et al. Enhanced excitability of myenteric AH neurones in the inflamed guinea-pig distal colon. J. Physiol. 547 (2003) 589-601
73. Arnold S.J., et al. Decreased potassium channel IKI and its regulator neurotrophin-3 (NT-3) in inflamed human bowel. Neuroreport 14 (2003) 191-195
74. Ferens D., et al. Effects of modulators of Ca2+-activated, intermediate-conductance potassium channels on motility of the rat small intestine, in vivo. Neurogastroenterol. Motil. 19 (2007) 383-389